bioRxiv (Cold Spring Harbor Laboratory)
January 29, 2026
Venkatesh Subramani, Timothy Nest, Annalisa Pascarella et al.
1 citation
Abstract Lysergic acid diethylamide (LSD) profoundly alters conscious experience, yet the electrophysiological mechanisms by which it reshapes neural dynamics remain incompletely understood. A hallmark of psychedelic states is widespread cortical desynchronization, typically inferred from reductions in spectral power, but whether such effects reflect genuine weakening of neural oscillations or...
International Journal of Innovative Technologies in Social Science
January 23, 2026
Jakub Klepacz, Radosław Swędrak, Marzena Swojnóg et al.
The escalating global burden of mental health disorders, coupled with the stagnation of innovation in traditional monoaminergic pharmacotherapy (e.g., SSRIs), has precipitated a critical need for novel therapeutic paradigms. This article presents a comprehensive systematic review of the so-called "Psychedelic Renaissance," focusing on the clinical resurgence of classical serotonergic...
Veterinary sciences
January 19, 2026
Elisa Hernández-Álvarez, Cristina Canino-Quijada, Sira Roiz et al.
Shelter environments frequently expose dogs to chronic stress and anxiety, which can compromise their welfare and reduce their chances of adoption. Recent interest in psychedelic-assisted approaches has suggested potential therapeutic applications in veterinary behavioral medicine, although empirical evidence remains scarce. This study aimed to evaluate the combined effects of low-dose...
Journal of psychopharmacology (Oxford, England)
January 13, 2026
James Glazer, Hanna Molla, Royce Lee et al.
Lysergic acid diethylamide (LSD) has been considered as a potential treatment for depression for over 75 years, but its therapeutic potential has only recently been considered in mainstream psychiatry. Repeated ingestion of low doses of LSD ("microdoses") is thought to reduce depression, but the neurobiology underlying this effect is unknown. We previously reported that low doses of LSD...
Brain Research
January 2, 2026
B.s. Rabinovitch, N. Silverman, D. Ji et al.
Background and rationaleLysergic acid diethylamide (LSD) is a promising therapeutic for psychiatric disorders, but its physiological profile on the nervous system remains elusive. Rodent electrophysiological data has utilized in vivo single-unit electrophysiology recordings, while clinical neurophysiology studies have focused on spectral signatures using electroencephalography (EEG) and...
Neuroscience and Biobehavioral Reviews
2026
Netta Pinhas, Nofar Eidlman, Avigail Barnea et al.
2 citations
Microdosing - the practice of consuming extremely low doses of classical psychedelic substances that do not elicit overt psychedelic effects - has gained significant attention as a potential method for enhancing cognitive performance. However, findings from controlled studies remain mixed and inconclusive. This preregistered meta-analysis examined the cognitive effects of classical psychedelic...
Forensic Science International
2026
Isabella Ferreira Melo, Leociley Rocha Alencar Menezes, Philippe Rodrigues Benedetti et al.
In recent decades, there has been a significant increase in the diversification and global commercialization of new psychoactive substances (NPS). This study assessed changes in the chemical profile of blotter papers and ecstasy tablets seized in the state of Paraná, Brazil, between 2014 and 2024. A total of 4911 samples (1656 blotter papers and 3255 tablets) were analyzed using GC-MS NMR, and...
Cureus
2026
Mohsin Raza, Jasleen Kaur
Psychedelic-assisted therapies have re-emerged as a subject of increasing scientific and clinical interest in psychiatry, particularly in the context of persistent treatment gaps for conditions such as treatment-resistant depression, post-traumatic stress disorder, and substance use disorders. Compounds, including psilocybin and 3,4-methylenedioxymethamphetamine, are being evaluated in...
Therapeutic advances in drug safety
2026
Ovie Martin Albert, Alexander Arthur
Psychedelic and psychedelic-adjacent substances, including 3,4-methylenedioxymethamphetamine (MDMA) and classic serotonergic hallucinogens, are undergoing renewed therapeutic investigation and remain in non-medical use. Inadvertent exposure during early, unrecognized pregnancy is clinically plausible, yet pregnancy-specific safety evidence is limited. To map and synthesize the extent,...
Therapeutic Advances in Psychopharmacology
2026
Kristian Beichmann, Polina Catzeflis, Helena Aicher et al.
The Swiss Federal Office of Public Health provides case-by-case exemptions allowing physicians to provide psychedelic-assisted therapy (PAT) using psilocybin, lysergic acid diethylamide (LSD), or 3,4-methylenedioxy-N-methamphetamine (MDMA). The study provided an overview of PAT as currently provided in Switzerland under the regulatory framework of the Federal Office of Public Health (FOPH)....
FOCUS The Journal of Lifelong Learning in Psychiatry
2026
Tyler Durns, Greg Iannuzzi
Psilocybin, lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA) have remerged as agents of psychiatric and cultural relevance. However, public discourse has outpaced empirical understanding of their effects. Although hallucinogens have demonstrated a potential to treat certain mental disorders, their effect on aggression and violence risk remains inconclusive. This...
Palliative & Supportive Care
2026
Fiona Cottam, Alesha Wells, Cerys Clayden et al.
Participation in trials investigating psychedelic-assisted MCP may offer hope for patients and their caregivers. Given the bidirectional relationship in wellbeing between cancer dyads, caregivers should be included alongside patients in such trials.
Neuroscience Applied
2026
A. Fernandez Ribas, V. Pérez Rodríguez, M. Paduraru
Hallucinogen Persisting Perception Disorder (HPPD) is a condition affecting 1-5% of psychedelic users, with higher prevalence observed among recurrentLSD consumers and synthetic cannabinoid users [1]. The disorder is characterised by persistent visual disturbances including palinopsia and visual snow, along with dissociative symptoms, which have been neurobiologically linked to 5-HT2A receptor...
Current Topics in Behavioral Neurosciences
2026
Tomislav Majić, Euphrosyne Gouzoulis‐mayfrank, Ricarda Evens
2 citations
Classic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), and 5-methoxy-dimethyltryptamine (5-MeO-DMT) have shown promising effects in the treatment of certain mental health conditions. Enthusiastic claims about their therapeutic potential have led to overly optimistic reactions in the media and the public, subsequently resulting in increased use outside of clinical contexts...
Figshare
2026
Kristian Larsen
This figure presents LSD occupancy at the serotonin 2A receptor (5-HT2AR) and global functional connectivity effects in healthy human participants for LSD and psilocybin. PET and fMRI acquisition, preprocessing, and statistical modelling procedures were pre-registered and are described in detail in the study protocol available on medRxiv (https://doi.org/10.1101/2025.06.17.25329677).
Figshare
2026
Kristian Larsen
This figure presents original population-level cerebral blood flow and global functional connectivity responses to LSD and psilocybin in healthy human participants. Peak drug effects are shown for cerebral blood flow and global connectivity, and within-subject associations between these measures are assessed using Spearman’s rank correlation. MRI acquisition, preprocessing, and statistical...